NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,195.60 -25.02 (-0.13%) CRUDE OIL
77.85 -0.81 (-1.03%) GOLD FUTURES
2,396.60 -29.30 (-1.21%) DOW
39,826.49 -46.50 (-0.12%) Bitcoin GBP
55,322.83 +310.89 (+0.57%)
BMY Aug 2024 52.500 call
| Previous close | 0.1000 |
| Open | 0.1200 |
| Bid | 0.1000 |
| Ask | 0.1200 |
| Strike | 52.50 |
| Expiry date | 2024-08-16 |
| Day's range | 0.1100 - 0.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.51k |
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PRINCETON, N.J., May 22, 2024--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
